Colorectal cancer screening in the COVID-19 era

World J Gastrointest Oncol. 2021 Apr 15;13(4):238-251. doi: 10.4251/wjgo.v13.i4.238.

Abstract

Colorectal cancer (CRC) is the third most diagnosed form of cancer and second most deadly cancer worldwide. Introduction of better screening has improved both incidence and mortality. However, as the coronavirus disease 2019 (COVID-19) pandemic began, healthcare resources were shunted away from cancer screening services resulting in a sharp decrease in CRC screening and a backlog of patients awaiting screening tests. This may have significant effects on CRC cancer mortality, as delayed screening may lead to advanced cancer at diagnosis. Strategies to overcome COVID-19 related disruption include utilizing stool-based cancer tests, developing screening protocols based on individual risk factors, expanding telehealth, and increasing open access colonoscopies. In this review, we will summarize the effects of COVID-19 on CRC screening, the potential long-outcomes, and ways to adapt CRC screening during this global pandemic.

Keywords: COVID-19; Colonoscopy; Colorectal cancer; Diagnostic screening programs; Early detection of cancer; Mass screening.

Publication types

  • Review